Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-06-27 / BMC Immunol. 2008 Jun;9:32The essential role of the in situ immune reaction in human colorectal cancer
/in Colorectal Cancer, International Publications /von 2008-06-17 / J. Leukoc. Biol. 2008 Oct;84(4):981-7Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2008-06-16 / Int. J. Urol. 2008 Aug;15(8):694-8Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
/in International Publications, Newcastle Disease Virus, NSCLC /von 2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-807Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen /von 2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-7Antitumor effect of lung cancer vaccine with umbilical blood dendritic cells in reconstituted SCID mice
/in International Publications, NSCLC /von 2008-06-01 / Cancer Biother. Radiopharm. 2008 Jun;23(3):321-31
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de